Exogenus T
Founded 2015 · 13 employees on LinkedIn · 1 known investors
Find your way into Exogenus T
13 people in our graph share verified history with the Exogenus T team — schools, employers, funds. One of them is your warm intro.
Kostas Alevizopoulosunlockedknows Joana Simões Correia · together at Exogenus T (overlapped)
×3knows the team · via Center for Neurosciences and Cell Biology (CNBC) - University of Coimbra
×8knows the team · via Center for Genomic Regulation
Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.
Founders & leadership
JS
Joana Simões CorreiainCEOJoana Simões Correia holds a PhD in Human Biology and has spent over 15 years in research on human diseases including cancer genetics and regenerative medicine. She co-founded and leads Exogenus Therapeutics, where she has directed the company's research and development activities since 2015 focusing on therapeutic exosomes derived from umbilical cord blood.
Investors · 1
Frequently asked questions
- What does Exogenus T do?
- Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.
- Who are Exogenus T's investors?
- Exogenus T's investors include 3xP Global.